BOSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a ...
– Prioritization of Phase 2-ready clinical-stage programs: RLYB212 for the prevention of FNAIT and RLYB116, a C5 inhibitor for the treatment of patients with complement-mediated diseases – – ...
This is a RAPS-SF Executives event exclusive for VP and above. This facilitated roundtable discussion event brings together industry leaders to explore how organizations are navigating two critical ...
New AI-native capabilities help organizations continuously prioritize initiatives, reduce redundancy, and move from idea to execution-ready plans faster. Enterprises aren't short on AI ideas. Business ...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced the prioritization of its portfolio and a 45% workforce reduction to focus resources on its Phase 2-ready ...
New AI-native capabilities help organizations continuously prioritize initiatives, reduce redundancy, and move from idea to execution-ready plans faster. TAMPA, Fla., May 20, 2026 /PRNewswire/ -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results